Cardiac mesoderm enhancer-associated non-coding RNA (CARMN)

Cardiac mesoderm enhancer-associated non-coding RNA (CARMN) is an evolutionarily conserved long non-coding RNA, originally characterized as a super enhancer-associated transcript critical for cardiac precursor cell fate and the maintenance of vascular smooth muscle cell homeostasis. CARMN serves as the host gene for the microRNAs miR-143 and miR-145, key regulators in cardiovascular development and disease as well as tumor suppression. CARMN is primarily nuclear and modulates gene expression through interactions with transcription factors (e.g., REST, myocardin, SRF), regulation of chromatin states, and involvement in RNA crosstalk (acting as a ceRNA). Its dysregulation is implicated in cardiovascular disease progression (e.g., atherosclerosis, aneurysm, heart failure) and several cancers, making it of growing interest for therapeutic targeting and biomarker discovery.

Other names

CARMENMIR143 and MIR145 host genemiR143HGNCR143/145

Not applicable for classic drug type; however, mechanisms of modulation could include: - Antisense inhibition or RNA interference targeting the lncRNA or the miR143/145 cluster - Pharmacological modulation of CARMN’s action as a competitive endogenous RNA (ceRNA) - Modulation of its interaction with chromatin regulators or transcription factors (such as REST, myocardin, or SRF)